AMRX Amneal Pharmaceuticals, Inc.

Did the company actually spend money buying back stock in 3+ of the last 4 quarters?

Not enough buyback data

Is the most recent quarter's buyback spend more than 15% above the trailing average?

Not enough buyback data

What percentage of free cash flow is going to buybacks? Bull: 30-80%. Bear: <10% or >80%.

Missing buyback or cash flow data

How fast are they shrinking the float? Bull: 2%+ annually. Bear: under 0.5%.

Missing shares repurchased or outstanding data

Are officers and directors buying stock with their own money on the open market?

9 open-market purchases by 6 insiders

• Patel Gautam () bought 50,000 shares at $4.21 on 2021-12-17
• Patel Chirag K. (President & Co-CEO) bought 50,000 shares at $4.25 on 2021-12-16
• Patel Chintu (Co-CEO) bought 50,000 shares at $4.25 on 2021-12-16
• Patel Chirag K. (President & Co-CEO) bought 100,000 shares at $4.13 on 2021-12-15
• Patel Chintu (Co-CEO) bought 100,000 shares at $4.13 on 2021-12-15
• Kiely John () bought 10,000 shares at $4.40 on 2020-05-19
• George Jeffrey P. () bought 23,810 shares at $4.16 on 2020-05-15
• MEISTER PAUL M () bought 204,210 shares at $2.71 on 2020-03-18
• MEISTER PAUL M () bought 149,439 shares at $2.79 on 2020-03-17

Are insider purchases happening during the same quarters the company is actively buying back stock?

Need both buyback and insider purchase data

Looking at all open-market transactions, are insiders net buyers or net sellers?

Insiders bought $3M, sold $75M (net selling)

Active buyback + insiders net selling 3x+ more than buying. Company cash may be supporting price while insiders exit.

No buyback-insider divergence detected